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ABSTRACT:
Gastric cancer is the second leading cause of cancer death and remains a major 
clinical challenge due to poor prognosis and limited treatment options. Therefore, the 
basic mechanisms underlying gastric tumorigenesis deserve investigation. Although 
regulation of the galactoside-binding lectin galectin-7 in cancer has been studied, 
its role in tumor formation and progression remains controversial. In this study, we 
investigated galectin-7 expression and its role in gastric cancer. Immunohistochemical 
staining using a tissue microarray of gastric cancer patients revealed significantly 
low expression levels of galectin-7 in malignant tissues compared with matched 
normal tissues, and decreased expression of galectin-7 in malignant tissues was 
associated with advanced TMN stage disease (p=0.034). Importantly, low expression 
of galectin-7 in normal tissues was associated with a poor survival rate (p=0.0561). 
Over-expression of galectin-7 in AGS gastric adenocarcinoma cells suppressed cell 
proliferation, migration, and invasion, whereas ablation of galectin-7 in KATO III 
gastric carcinoma cells reversed these properties. AGS cells that overexpressed 
galectin-7 could not form gastric tumors in xenografted mice. More than 70% 
hypermethylation was observed in 7 of 9 gastric cancer cell lines tested and 5-aza-
cytidine treatment lowered galectin-7 expression by reducing methylation in 24 cancer 
cell lines from five different organ origins. We analyzed CpG islands in the galectin-7 
genomic region and detected hypermethylation at +1566bp of exon 2, the predicted 
p53 binding region. DNA hypermethylation of this region was also detected in gastric 
cancer tissues from 20 patients. Taken together, our data indicate that galectin-7 
has a tumor suppressive function, and that the gene is epigenetically modified by 
DNA methylation and significantly down-regulated in gastric cancer. Further study 
of galectin-7 regulation may lead to improved gastric cancer diagnosis and therapy. 
INTRODUCTION
Galectin-7 is a member of a family of proteins with 
affinity for β-galactosidase–containing oligosaccharides. 
Galactin-7 contains one carbohydrate recognition domain 
(CRD) in its biological structure and functions as a 
homodimer [1-2]. In contrast to other galectins such as 
galectin-1 and -3, the function of galectin-7 is still largely 
unknown. It is known to interact with a wide range of 
potential receptors, including non-reducing terminal 
LacNac residues and internal LacNac oligosaccharide 
residues, but its carbohydrate binding affinity is weaker 
than that of galectin-1 and -3 [3]. It has been suggested 
that the function of galectin-7 may vary according to its 
cellular localization because the protein is present in the 
nucleus and the cytoplasm, and also in the cell-to-cell 
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contact region. 
Research performed over the last two decades has 
shown that galectin-7 is associated with the differentiation 
and development of epithelia, including epithelial cell 
migration and epidermal wound healing [4-5]. The 
regulation of apoptosis induction by galectin-7 also has 
been studied [6-9]. This regulation is thought to involve 
JNK activation, mitochondrial cytochrome c release, and 
Bcl2 binding in the mitochondrial membrane. In addition, 
there are several reports of a role of galectin-7 in cancer 
development. Altered galectin-7 expression is involved 
in tumor progression through the regulation of cell 
proliferation, apoptosis induction, and cell invasion [9-12]. 
Interestingly, galectin-7 may contribute to the suppression 
of cancer proliferation in certain tumor types and induce 
the growth and metastasis of others. For the suppressive 
function, galectin-7 was identified as a p53-induced 
gene 1 (PIG1) and was shown to reduce neuroblastoma 
cell proliferation [10]. Etopic expression of galectin-7 
in cancer cells increased their susceptibility to apoptosis 
and suppressed tumor growth [7, 11]. Both galectin-7 and 
S100A9 were found to play protective roles in cervical 
squamous carcinomas [13]. In contrast, stimulatory roles 
of galectin-7 in cancer development have also been widely 
demonstrated. Over-expression of galectin-7 modulated 
the aggressive behavior of lymphoma cells through 
expression of the metastasis-related gene MMP-9 [12] and 
the expression of galectin-7 was increased in rat mammary 
carcinomas induced by carcinogen [14]. High expression 
of galectin-7 in breast cancer cells induced their ability 
to metastasize to lungs and bones, and many breast 
carcinoma samples contain more than 70% galectin-7–
positive cells [15]. Therefore, the precise role of galectin-7 
in cancer development is still debated and appears to be 
tissue specific, which we find fascinating. Moreover, the 
role of galectin-7 in gastric cancer has not been studied.
In this study, we first determined the differential 
expression of galectin-7 in gastric cancer cell lines and 
tissues from gastric cancer patients compared with 
matched normal tissue. We found that the expression 
of galectin-7 was down-regulated in malignant tissues 
from gastric cancer patients and was regulated by 
DNA methylation of CpG islands in regulatory regions 
containing a putative p53 binding site. Over-expression of 
Characteristic
Galectin-7 expression
Normal Tumor
Low (N = 30) High (N =14) P value Negative (N = 25) Mild (N = 16) Moderate (N = 3) P value 
Sex 0.602 0.206
Male 19 10 18 10 1
Female 11 4 7 6 2
Age (years) 0.408 0.626
<60 11 7 9 8 1
≥60 17 7 16 8 2
Differentiation 0.344 0.550
Well 3 1 3 1 0
Moderately 8 2 4 5 1
Poorly 12 8 14 4 2
other 7 3 4 6 0
Lauren's classification 0.669 0.499
Intestinal 13 5 8 9 1
Mixed 1 0 17 6 2
Diffuse 16 9 0 1 0
T classification 0.568 0.034*
T1 5 3 3 4 1
T2 3 2 2 2 1
T3 14 6 11 8 1
T4 8 3 9 2 0
LN metastasis 0.895 0.282
Negative 8 4 8 4 0
Positive 22 10 17 12 3
TNM stage 0.568 0.148
I 5 3 3 4 1
II 8 6 8 5 1
III 15 5 12 7 1
IV 2 0 2 0 0
Table1
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galectin-7 suppressed cell proliferation in p53 wild-type 
AGS gastric cancer cells. Taken together, these findings 
suggest that galectin-7 has a suppressive role in gastric 
cancer and that its expression is regulated by epigenetic 
mechanisms such as DNA methylation.
RESULTS
Galectin-7 expression is down-regulated in 
malignant tissues from gastric cancer patients 
relative to matched normal tissue 
To determine the expression levels of galectin-7 
in gastric cancer patients, we prepared a tissue 
microarray (TMA) of 44 patients and performed 
immunohistochemical analysis (Table 1 and Figure 1A). 
Strong expression was detected in normal tissues from 
patients with intestinal and diffuse types of gastric cancer 
and most of the galectin-7 was localized in the cytosol. 
Expression was notably down-regulated in gastric cancer 
tissues (Figure 1A). Quantitative analysis of galectin-7 
staining confirmed that gastric cancer patients had low or 
no expression in malignant tissues compared with normal 
tissues (Figure 1B). As shown in Table 1, we statistically 
analyzed the expression levels with respect to clinical 
factors. The protein expression levels of galectin-7 in 
malignant tissues were significantly decreased in patients 
with advanced stage disease by T classification (p=0.034) 
(Table 1). Moreover, the survival probability was higher 
in gastric cancer patients with high galectin-7 expression 
in normal tissues (p=0.0561) (Figure 1C) although 
this was not statistically significant, possibly due to the 
limited number of samples. Our data strongly indicate 
that galectin-7 is down-regulated during gastric cancer 
progression.
Over-expression of galectin-7 suppressed 
proliferation, migration, and invasion of AGS 
gastric cancer cells.
We next investigated the role of galectin-7 in the 
progression in gastric cancer cells. First, we examined 
the expression levels of galectin-7 mRNA and protein in 
Figure 1: Expression levels of galectin-7 in malignant and normal tissues of 56 gastric cancer patients. (A) In situ expression 
of galectin-7 in normal and tumor tissue from gastric cancer patients of intestinal and diffuse type was detected by immunohistochemical 
(IHC) analysis and hematoxylin and eosin (H&E) staining (magnification: ×200, ×400). (B) Comparative analysis of galectin-7 expression 
in normal and tumor tissues of gastric cancer patients based on intensity of galectin-7 staining. p values (*, p<0.001) were calculated 
using Student’s t-test. (C) Kaplan-Meier analysis of survival curves for patients with gastric cancer (N = 44) according to the expression 
of galectin-7 in normal tissues. The galectin-7 low-expression group showed a much lower survival rate at 125 months compared with the 
galectin-7 high-expression group.
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nine gastric cancer cell lines (Figure 2A). KATO III and 
SNU-16 cell lines showed high expression of galectin-7 
whereas the other cell lines expressed low levels of 
galectin-7. We selected AGS gastric cancer cells with low 
expression of Galectin-7 and transiently transfected them 
with the expression vector pQE-9-galectin-7 for 48 h. 
Over-expression of galectin-7 was confirmed by western 
blotting (Figure 2B). Galectin-7 over-expression inhibited 
cell proliferation as measured by crystal violet staining 
(Figure 2B) and WST assay (Figure 2C), and significantly 
decreased gastric cancer cell migration and invasion, 
(Figure 2D and E). These findings suggest that galectin-7 
functions as a tumor suppressor in gastric cancer.
Ablation of galectin-7 increased proliferation, 
migration, and invasion of KATO III gastric 
cancer cells.
We also determined the effect of loss of function of 
galectin-7 in KATO III gastric cancer cells, which have 
high expression levels of galectin-7. Cells were transfected 
with scrambled RNA (scRNA) as a negative control 
and galectin-7 specific siRNA. Ablation of galectin-7 
increased cell proliferation (Figure 3A and B), migration 
(Figure 3C), and invasion (Figure 3D). Those results 
support the notion that galectin-7 is a tumor suppressor in 
gastric cancer.
Effect of in vivo galectin-7 over-expression in 
gastric cancer cell xenografted mice
We prepared stable galectin-7 over-expressing 
AGS cells and inoculated them into nude mice (Figure 
4). Although tumors were formed from AGS cells 
expressing vector control pcDNA 3.0, the galectin-7 over-
expressing AGS cells could not form gastric tumors in 
the xenografted mice (Figure 4). These results strongly 
suggest that galectin-7 prevents gastric cancer formation 
and progression.
Figure 2: Over-expression of Galectin-7 suppressed proliferation, migration, and invasion of AGS gastric cancer cells. 
(A) mRNA and protein expression of galectin-7 in nine gastric cancer cell lines by RT-PCR and western blot. GAPDH and β-actin were 
used as loading controls. (B-E) AGS cells were transfected with pQE control vector and pQE-galectin-7 expression vector for 48 h. (B) 
Western blot analysis of galectin-7 protein expression and crystal violet staining of cells, (C) Cell proliferation measured by WST assay, (D) 
Cell migration assay, (E) Cell invasion assay. For cell migration and invasion assays the p value (* p<0.0001 vs. scRNA) was calculated 
using Student’s t-test.
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DNA hypermethylation in the region of the CpG 
islands at +1566 bp in exon 2 of the galectin-7 
gene in gastric cancers
To analyze the regulatory mechanism of galectin-7 
expression we studied DNA demethylation by 5-aza-
dC treatment. Galectin-7 mRNA expression was greatly 
increased in five cell lines, AGS, YCC-2, SNU-1, SNU-
601 and SNU-638, following 5-aza-dC treatment (Figure 
5A), suggesting that DNA methylation suppresses 
galectin-7 gene expression in these gastric cancer cell 
lines. 
Next, we quantitatively analyzed the methylation 
status of galectin-7 in nine gastric cancer cell lines. As 
shown in Supplementary figure 1A, there are three CpG 
islands between -3000 and +2550 of the LGALS7 gene. 
Among these CpG islands, we chose a 1.6-kb region (+912 
to +2550) including the CpG sites at +1450 and +1800, 
and analyzed five amplicons as shown in Supplementary 
figure 1B, such that 43 CpG sites per sample were 
analyzed. Primers were designed using EpiDesigner 
software (http://www.epidesigner.com), and the sequences 
are shown in Supplementary figure 1C. According to 
Figure 5B and Supplementary figure 2, we detected more 
than 80% methylation in the CpG islands at +1566 bp of 
exon 2 of galectin-7 in seven of the nine gastric cell lines 
tested. In contrast, the methylation status in KATOIII and 
SNU16 cell lines was lower than 40%, consistent with 
previous results. To confirm whether down-regulation of 
galectin-7 in gastric cancer cell lines depends on promoter 
methylation, we treated nine gastric cancer cell lines 
with 5-aza-dC and quantitatively monitored the change 
in methylation status by the EpiTYPERTM assay (Figure 
5 B and supplementary figure 2). After treatment with 
5-Aza-dC, the CpG island at +1566 bp of exon 2 was 
demethylated about 20% in all cell lines except SNU216 
(Figure 5 B and supplementary figure 2). These data 
indicate that the region of CpG islands at +1566 bp in 
exon 2 of galectin-7 is highly methylated in gastric cancer.
5-Aza-dC treatment increased mRNA expression 
of galectin-7 in 26 cancer cell lines from five 
different organ origins
To further determine the importance of DNA 
methylation in the regulation of galectin-7 gene expression 
Figure 3: Ablation of Galectin-7 increased proliferation, migration, and invasion of KATO III gastric cancer cells. 
KATO III cells were transfected with scrambled RNA (scRNA) as a negative transfection control and galectin-7 siRNA for 48 h. (A) Cell 
proliferation using WST assay, (B) detection of galectin-7 protein expression by Western blot and staining with crystal violet, (C) cell 
migration assay, (D) cell invasion assay. For the cell migration and invasion assays the p value (* p<0.0001 vs. scRNA) was calculated 
using Student’s t-test.
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in various tumor cells, we treated 26 cancer cell lines from 
five different organ origins with 50 nmol/L 5-Aza-dC and 
performed RT-PCR analysis (Figure 6A) and real-time RT-
PCR analysis (Figure 6B). Galectin-7 expression levels 
in various tumor cell lines markedly increased following 
treatment with 5-aza-dC as listed in Supplementary table 
1. From the 26 cell lines we choose 6 breast cancer cell 
line and 8 lung cancer cell lines for MS-PCR analysis. 
As shown in Figure 6C, the test region of galectin-7 was 
hypermethylated in these cancer cell lines. Taken together, 
our results indicate that galectin-7 expression is regulated 
by DNA methylation in various cancer cell lines from 
different organ origins, including gastric cancer cell lines. 
DISCUSSION
Gastric cancer is difficult to cure unless it is found at 
an early stage before it has begun to spread. Unfortunately, 
because early stomach cancer causes few symptoms, the 
disease is usually advanced when the diagnosis is made 
[16]. Treatment for stomach cancer may include surgery, 
chemotherapy, and/or radiation therapy. Even patients 
who present in the most favorable condition and undergo 
curative surgical resection often die of recurrent disease 
[17]. Therefore, it is extremely important to discover a 
biomarker to determine the condition or stage of gastric 
cancer in order to improve patient survival. In this study, 
we suggest that galectin-7 functions as a gastric cancer 
suppressor. We show that the expression of galectin-7 was 
lower in malignant tissues than normal gastric tissues, and 
over-expression of galectin-7 suppressed the proliferation, 
migration, and invasion of gastric cancer cells. However, 
the role of galectin-7 in cancer tumorigenesis remains 
unclear because there are several conflicting reports of 
galectin-7 function. At first, galectin-7 was considered a 
pro-apoptotic factor via p53 [6-7, 10-11, 18]. However, its 
role in promoting tumor malignancy was also described 
in several reports [19-21], and galectin-7 expression was 
linked to increased metastatic phenotype in breast cancers 
[15] and migration of corneal epithelial cells [22]. The 
increase in tumor malignancy and metastatic phenotype 
were attributed to the induction of MMP-9 expression by 
galectin-7 [12, 23-24]. Therefore, we aimed to elucidate 
the mechanism by which galectin-7 suppresses gastric 
cancer proliferation and invasion. 
Our data suggest that the expression of galectin-7 
in gastric cancer is regulated by DNA hypermethylation. 
Aberrant DNA methylation has been shown to be involved 
in gastric tumourigenesis, suggesting that it may be a 
useful clinical biomarker for the disease [16, 25-27]. DNA 
methylation is an epigenetic mechanism of transcriptional 
regulation, and its involvement in cancer is attributed to 
inappropriate silencing of tumor suppressor genes or loss 
Figure 4: The effect of galectin-7 over-expression on tumor growth of xenografts in nude mice. AGS SQ cells (100 µl; 1 × 
106 cells) in Matrigel were implanted into Balb/c-nude mice to form subcutaneous xenografts. After 8 weeks the mice were sacrificed, the 
tumors were photographed (A), and tumor size (B) and weight (C) were measured. The p value for tumor size and weight (* p=0.048 and 
0.0234 vs. Mock groups) was calculated using Student’s t-test.
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of oncogene repression [28-29]. Gastric cancer studies 
have shown that more than 100 genes exhibit aberrant 
DNA methylation, including significant changes in 
methylation of a number of genes commonly implicated 
in tumorigenesis, such as MLH1, p16, CHFR, and RUNX3 
[16, 25-27, 30], and DNA methylation of these genes might 
be useful for gastric cancer screening, prognostication, and 
treatment prediction. Here, we demonstrated diminished 
expression of galectin-7 in malignant tissues relative to 
matched normal tissues in 70% of gastric cancer patients, 
and also detected DNA methylation of the galectin-7 gene 
in malignant tissues of other gastric cancer patients. The 
observed increase in expression of galectin-7 in gastric 
cancer cell lines following 5-aza-dC treatment strongly 
supports the involvement of epigenetic regulation 
in cancer cell-specific expression. Interestingly, the 
hypermethylation region in galectin-7 is a predicted p53 
binding site, suggesting an association with p53 function 
(Supplementary figure 3). Galectin-7 is considered a 
p53 inducible gene [10] and we also detected increased 
expression of gamectin-7 by DNA damaging agents 
such as Adriamycin (data not shown). It is possible that 
galectin-7 expression is less affected by p53 when under 
hypermethylation. However, the correlation between 
galectin-7 hypermethylation and transcriptional regulation 
by p53 requires further study. We also detected DNA 
hypermethylation in 24 among 26 cancer cell lines from 
five different organ origins. Therefore, we propose that 
the expression of galectin-7 is critically regulated by 
DNA hypermethylation and might play a role in gastric 
cancer tumorigenesis and as a prognostic marker of gastric 
cancer. 
In conclusion, given the importance of early 
detection for improving gastric cancer survival outcomes, 
the results of this study indicate that DNA methylation 
of galectin-7 is a promising candidate biomarker for 
application in gastric cancer. However, it is necessary to 
analyze a larger number of gastric cancer patient samples 
to confirm these findings. Moreover, the role of galectin-7 
in gastric tumorigenesis should be further examined in 
future studies.
METHODS
Cell culture 
The following cell lines were obtained from 
American Type Culture Collection (Manassas, VA) and 
Figure 5: Galectin-7 was hypermethylated in gastric cancer cells and in malignant tissues of gastric cancer patients. 
(A) mRNA expression of galectin-7 in nine gastric cancer cell lines following treatment with 50 nmol/L 5-Aza-dC. GAPDH was used as 
a loading control. (B) MSP analysis of the galectin-7 gene in 9 gastric cancer cell lines (C) and 20 gastric cancer patients. The methylated 
(M) and unmethylated (U) DNA was amplified using primers specific for each methylation status. Universal methylated DNA was used 
as a positive loading control. (D) Epityper Comparison of methylation patterns in nine gastric cancer cell lines (AGS, MKN28, KATOIII, 
YCC-2, SNU-1, SNU-16, SNU-216, SNU-601, SNU-638) after treatment with 50 nmol/L 5-Aza-dC. 
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the Korea Cell Line Bank: six breast cancer cell lines 
(MDAMB231, MCF-7, T47D, Hs-578T, SK-BR-3, ZR-
75-1), three colon cancer cell lines (LOVO, HT-29, RKO), 
eight lung cancer cell lines (A549, H358, H460, H596, 
NCIH-146, NCIH-1703, HCC1195, SK-Lu-1), eight liver 
cancer cell lines (SNU-449, SNU-398, SNU-475, Hep3B, 
PLC/PRF5, SNU-354, SNU-423, SNU-387), one prostate 
cancer cell line (LNCap), and seven gastric cancer cell 
lines (AGS, MKN28, KATOIII, YCC-2, SNU-1, SNU-16, 
SNU-216, SNU-601, SNU-638). The ATCC and KCLB 
authenticate the phenotypes of these cell lines. The cells 
were treated with 50 nmol/L 5-aza-2V-deoxycytidine 
(5-Aza-CdR; Sigma Chemical Company, St. Louis, MO, 
USA) for 3 days in three independent experiments. 
Tissue samples from gastric cancer patients
Two pairs of 2-mm tissue biopsy specimens were 
obtained from 20 patients with gastric adenocarcinoma 
during diagnostic endoscopy and endoscopic submucosal 
dissection. All experiments were approved by the 
Institutional Review Board of the National Cancer 
Center, approval number NCCNSH 03-024. All 
participants provided written informed consent for 
the use of tissues for comprehensive experiments on 
gastric cancer. For immunohistochemical analysis, 
core tissue biopsy specimens (2-mm diameter) were 
obtained from Superbiochips Laboratories (Seoul, 
Korea). Immunohistochemical analysis was performed as 
described previously [31-32] and anti-galectin-7 antibody 
was kindly provided by Moon-jae Cho (Jeju University).
Generation of galectin-7 over-expressing gastric 
cancer xenografts in mice 
All animal experiments were approved by the 
Yonsei University Medical School animal care and use 
committee (2012-0132) and were performed in specific 
pathogen-free facilities under conditions in accordance 
with the Guidelines for the Care and Use of Laboratory 
Animals of YUMS. The preparation of xenografted mice 
has been described in a previous study [31]. Galectin-7 
overexpression vector pQE-9-Galectin-7, kindly provided 
by Moon-jae Cho (Jeju University), was transiently 
transfected into cells using Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s instructions. 
Figure 6: Up-regulation of galectin-7 expression in various cancer cell lines. (A-B) mRNA expression of galectin-7 in 26 
cancer cell lines detected by RT-PCR (A) and RT-qPCR (B). β-actin was used as a loading control. (C) MSP analysis of the galectin-7 gene 
in 14 cancer cell lines. The methylated (M) and unmethylated (U) DNA was amplified using primers specific for each methylation status. 
Universal methylated DNA was used as a positive loading control.
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Western blot analysis
Western blot analysis was carried out using 
methodology from a previous study [32]. The primary 
antibodies for galectin-7 and β-actin, and HRP-conjugated 
goat anti-mouse or goat anti-rabbit IgGs were purchased 
from Santa Cruz Biotechnology and the signals were 
detected using an enhanced chemiluminescence (ECL) 
plus kit (Amersham Life Science) and a LAS-3000 
(Fujifilm) detector according to the manufacturer’s 
directions.
RNA isolation, reverse transcription-polymerase 
chain reaction (RT-PCR), and quantitative PCR 
analysis
RNA was isolated using TRIzol○RRReagent 
(Invitrogen) according to the manufacturer’s 
instructions and RT-PCR was performed using a 
Reverse Transcription system (Promega, Madison, 
WI, USA). The primers used were as follows: 
Galectin-7, 5’-ATGTCCACCGTCCCCCACAAG-3’ 
and 5’-TGACGCGATGATGAGCACCTC-3’; 
β-actin; 5’-AGCCTCGCCTTTGCCGA-3’ and 5’- 
CTGGTGCCTGGGGCG-3’. PCR was performed 
following Ex-taq (TaKaRa, Shiga, JAPAN) protocols. 
Real-time PCR analysis of the galectin-7 gene was 
performed using ABI PRISM (Applied Biosystems) 
according to the manufacturer’s instructions 
with the following primer sequences specific for 
Galectin-7: 5’-CCTTCGAGGTGCTCATCATC-3’ and 
5’-GAAGATCCTCACGGAGTCCA-3’. cDNA was 
used as a template and product was detected with the 
intercalating agent SYBR green I dye. 
Bisulfite conversion
The first step of methylation analysis is bisulfite 
conversion of genomic DNA. Bisulfite treatment 
converts cytosine to uracil (thymine in DNA) by 
bisulfite-deamination, but in 5-methyl cytosine the 
position 5-methyl group inhibits deamination of the 
amino group. Therefore, 5-methyl cytosine remains as 
cytosine but unmethylated cytosine is converted to uracil. 
One microgram of gDNA was bisulfite treated using 
the EZ DNA Methylation-Gold Kit according to the 
manufacturer’s instructions with a GeneAmp PCR system 
9700 (Applied Biosystems). Briefly, 1 µg of gDNA was 
mixed with bisulfite treatment solution and incubated at 
98°C for 10 min and 64°C for 150 min. Samples were 
loaded onto a column, washed with ethanol solution, and 
incubated with desulphonation solution for 20 minutes 
at room temperature. After washing, the bisulfite-
treated DNA was eluted and analyzed using a Nanodrop 
spectrophotometer (Thermo Scientific). 
Quantitative analysis of DNA methylation 
For quantitative analysis of the DNA methylation 
status of the LGALS7 gene, we searched the promoter 
sequence using the “Transcriptional Regulatory 
Element Database” freeware program and designed 
primer sequences (+912 to +2250) using SEQUENOM 
EpiDesigner software as shown in Supplementary figure 
1A.
Methylation-specific PCR
PCR primers were designed using the Meth primer 
v1.1 beta version Software to amplify a region from 
-3000 to +2550 within the galectin-7 (LGALS7) gene 
(Supplementary Fig 1B). This primer set was used to 
verify the presence of the galectin-7 gene in cancer cell 
lines and gastric cancer patient tissues and for sequencing 
of the promoter region. An unmethylated (U)-specific 
set of primers: TTTTAATTTTTGGTTGGATATGTTG 
(forward) and CTCCAAAAACCTAAATCTTAA CATC 
(reverse), and a methylated (M)-specific set of primers: 
TTTAATTTTCGGTTGGATACGTC (forward) and 
CTCCAAAAACCTAAATCTTAACGTC (reverse) were 
designed based on the positive strand of the bisulfite-
converted DNA and spanned a region within the CpG 
island of the promoter. The experiments were performed 
as described previously [33].
Statistical Analysis
Data for cell proliferation, cell migration, and 
invasion assay were obtained from at least three 
independent experiments and are presented as mean 
± SD, unless otherwise indicated. Statistical analysis 
was performed using Student’s t-test. The Χ2 test was 
conducted to determine the significance of the difference 
between covariates. Survival durations were calculated by 
the Kaplan-Meier method. The log-rank test was used to 
compare cumulative survival among the patient groups. 
Statistical significance was set at p<0.05 throughout the 
study. The Med-Calc software program (version 11.4; 
MedCalc Software, Mariakerke, Belgium) was used for 
all analyses.
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